Center-Authored Papers

Filters: Author is Gray, Glenda  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Viral Load
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract
Vaccine and Infectious Disease Institute
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Vaccine and Infectious Disease Division
Piwowar-Manning E, Fiamma A, Laeyendecker O, Kulich M, Donnell D, Szekeres G, Robins-Morris L, Mullis CE, Vallari A, Hackett J et al..  2011.  HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043).. BMC infectious diseases. 11:251. Abstract
Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.  2012.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Statistical Communications in Infectious Diseases. 3(1)
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract
Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV et al..  2011.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.. AIDS research and human retroviruses. 27(5):557-567. Abstract
Coates TJ, Kulich M, Celentano DD, Zelaya CE, Chariyalertsak S, Chingono A, Gray G, Mbwambo JKK, Morin SF, Richter L et al..  2014.  Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. The Lancet Global Health. 2(5):e267-e277. Abstract
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
Perti T, Nyati M, Gray G, de Bruyn G, Selke S, Magaret A, Huang M-L, Velaphi S, Corey L, Wald A.  2014.  Frequent Genital HSV-2 Shedding among Women during Labor in Soweto, South Africa.. Infectious diseases in obstetrics and gynecology. 2014:258291. Abstract
Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk D, Mullis CE, Chin C, Swanson P, Hackett J et al..  2013.  Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043).. PloS one. 8(7):e68349. Abstract
Specimen Processing Core Facility
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
Perti T, Nyati M, Gray G, de Bruyn G, Selke S, Magaret A, Huang M-L, Velaphi S, Corey L, Wald A.  2014.  Frequent Genital HSV-2 Shedding among Women during Labor in Soweto, South Africa.. Infectious diseases in obstetrics and gynecology. 2014:258291. Abstract
South Africa
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract
Shared Resources
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
sexually transmitted diseases
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Sexual Partners
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
September 2011
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
RNA, Viral
Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret AS, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A et al..  2009.  Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.. PloS one. 4(4):e5272. Abstract
Research Trials Office Core Facility - Biostatistics Service
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
Perti T, Nyati M, Gray G, de Bruyn G, Selke S, Magaret A, Huang M-L, Velaphi S, Corey L, Wald A.  2014.  Frequent Genital HSV-2 Shedding among Women during Labor in Soweto, South Africa.. Infectious diseases in obstetrics and gynecology. 2014:258291. Abstract
pol Gene Products, Human Immunodeficiency Virus
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract
Placebos
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract
November 2011
Piwowar-Manning E, Fiamma A, Laeyendecker O, Kulich M, Donnell D, Szekeres G, Robins-Morris L, Mullis CE, Vallari A, Hackett J et al..  2011.  HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043).. BMC infectious diseases. 11:251. Abstract
nef Gene Products, Human Immunodeficiency Virus
Gray G, Buchbinder S, Duerr A.  2010.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61. Abstract